Johnson & Johnson expected to see decrease in earnings, but revenue projected to rise; FDA approval positive.

From Financial Modeling Prep: 2025-01-22 04:09:17

Johnson & Johnson (NYSE:JNJ) is expected to see a decrease in earnings per share to $2.02 from $2.29, but revenue is projected to rise to $22.45 billion, showing a positive sales trend. The FDA approval of Spravato nasal spray for expanded use could potentially increase future sales for the company.

Analysts anticipate Johnson & Johnson to report earnings of $2.02 per share for the fourth quarter, down from $2.29 per share last year. Despite this decline, revenue is expected to increase to $22.45 billion, up from $21.39 billion, indicating a positive sales performance.

The FDA’s approval of Johnson & Johnson’s Spravato nasal spray for expanded use as a standalone treatment for adults with major depressive disorder could boost future sales. This approval enhances the company’s psychiatric drug portfolio.

Johnson & Johnson’s stock price closed at $148.15, with shares increasing by 0.8% ahead of the earnings announcement. The company’s market capitalization is approximately $356.69 billion, with a trading volume of 8,262,191 shares. Stock performance has seen some volatility over the past year.



Read more at Financial Modeling Prep:: Johnson & Johnson (NYSE:JNJ) Neutral Rating and Fi…